Drug class
Bispecific monoclonal antibody; CD20×CD3 T-cell-engaging immunotherapy
Mechanism of action
Binds CD20 on B-lineage cells and CD3 on T cells, bringing T cells into close proximity with malignant B cells and promoting T-cell-mediated cytotoxicity against CD20-expressing cells.
General use cases
- Investigational treatment studied in adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma; this is not a statement of a universal marketing authorisation.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
